Pathogenetic molecular mechanisms of chronic rhinosinusitis with nasal polyps associated with asthma

The combination of bronchial asthma (BA) and chronic rhinosinusitis with nasal polyps (CRSwNP) is currently considered a separate phenotype wit1 dysregulation of pro- and anti-inflammatory cytokines as one of t1e leading causes of inflammation. The aim of this study was to investigate the local and systemic inflammatory process in patients with BA associated with CRSwNP. Methods. The study enrolled 96 volunteers divided into 4 groups: the 1^st was healthy control (Normal); the 2^nd had allergic BA associated with CRSwNP; the 3^rd had nonallergic BA associated with CRSwNP; the 4^th had CRSwNP without BA. All participants of the study underwent clinical, laboratory, instrumental, and histological examinations. The expression of il-1β, il-4, il-,5 il-6, il-13, il-37, il-17f, ifn-γ, tnf-α and tgf-β genes was assessed in the peripheral blood mononuclear cells - PBMC and in the polyp tissue using RT-PCR. We also estimated the expression of tslp, il-25 and il-33 in the polyp tissue and expression of GATA3 and RORgt transcription factors in PBMC. Results. The pathogenesis of BA associated with CRSwNP is characterized by the dys-regulation of the local pro- and anti-inflammatory cytokines of the Th1-, Th2-, Th17- immune response. Moreover, the high expression of il-37 gene in patients with BA associated with CRSwNP, and especially in patients with not-allergic BA associated with CRSwNP, probably indicates the «inclusion» of the compensatory mechanism. In addition, BA associated with CRSwNP is characterized by severe course of both diseases. A nonallergic BA associated with CRSwNP is characterized by more pronounced eosinophilic inflammation, which is an unfavorable prognostic factor. Conclusion. Thus, a comparison of the levels of local and systemic cytokine expression in patients with BA associated with CRSwNP led to the conclusion that CRSwNP affects the local immunity more than systemic immunity. However, the latter is affected to some extent in the long-term as well.

1. Shilovskiy I.P., Dyneva M.E., Kurbacheva O.M. et al. [The role of interleukin-37 in the pathogenesis of allergic diseases]. Acta Naturae. 2019; 11 (4): 54-64. DOI: 10.32607/20758251-2019-11-4-54-64 (in Russian).

2. Dyneva M.E., Kurbacheva O.M., Savlevich E.L. [Bronchial asthma in combination with chronic rhinosinusitis with nasal polyps: epidemiology, prevalence and peculiarities of their relationship]. Rossiyskiy allergologicheskiy zhurnal. 2018; 15 (1-1): 16-25 (in Russian).

3. Global Initiative for Asthma. 2019 GINA Report, Global Strategy for Aasthma Management and Prevention. Available at: https://ginasthma.org/reports/2019-gina-report-global-strategy-for-asthma-management-and-prevention/ [Accessed: May 11, 2020].

4. Kim D.W., Cho S.H. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol. Res. 2017; 9 (4): 299-306. DOI: 10.4168/aair.2017.9.4.299.

5. Fokkens W.J., Lund V.J., Mullol J. et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinology. 2012; 50 (Suppl. 23): 1-298. Available at: http://rhinology.ru/wp-content/uploads/2016/10/03-epos-2012.pdf

6. Serrano E., Neukirch F., Pribil C. et al. Nasal polyposis in France: impact on sleep and quality of life. J. Laryngol. Otol. 2005; 119 (7): 543-549. DOI: 10.1258/0022215054352108.

7. Savlevich E.L., Gaganov L.E., Egorov V.I. et al. [A comparative pilot study of antipov polosnogo chronic rhinosinusitis patients living in different geographical regions of the Russian Federation]. Immunologiya. 2018; 39 (4): 208-213 (in Russian).

8. Kurbacheva O.M., Pavlova K.S. [Phenotypes and endotypes of bronchial asthma: from pathogenesis and clinical features to therapy]. Rossiyskiy allergologicheskiy zhurnal. 2003; (1): 15-24 (in Russian).

9. Chaaban M.R., Walsh E.M., Woodworth B.A. Epidemiology and differential diagnosis of nasal polyps. Am. J. Rhinol. Allergy. 2013; 27 (6): 473-478. DOI: 10.2500/ajra.2013.27.3981.

10. Savlevich E.L., Dyneva M.E., Gaganov L.E. et al. [Diagnostic and treatment algorithm for different phenotypes of chronic rhinosinusitis with nasal polyps].Rossiyskiy allergologicheskiy zhurnal. 2019; 16 (2): 50-60 (in Russian).

11. Soler Z.M., Mace J.C., Litvack J.R., Smith T.L. Chronic rhinosinusitis, race, and ethnicity. Am. J. Rhinol. Allergy. 2012; 26: 110-116. DOI: 10.2500/ajra.2012.26.3741.

12. Stevens W.W., Peters A.T., Hirsch A.G. et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract. 2017; 5 (4): 1061-1070.e3. DOI: 10.1016/j.jaip.2016.12.027.

13. Mortuaire G., Gengler I., Balden M. et al. Impact of allergy on phenotypic and endotypic profiles of nasal polyposis. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2018; 135 (3): 159-162. DOI: 10.1016/j.anorl.2017.11.005.

14. Lin D.C., Chandra R.K., Tan B.K. et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am. J. Rhinol. Allergy. 2011; 25 (4): 205-208. DOI: 10.2500/ajra.2011.25.3613.

15. Chichkova N.V. [Bronchial asthma and polyposis rhinosinusitis: features of clinical treatment and management of patients]. Astma i allergiya. 2015; (1): 19-22 (in Russian).

16. Yacoub M.R., Trimarchi M., Cremona G. et al. Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps? Clin. Mol. Allergy. 2015; 13 (1): 23. DOI: 10.1186/s12948-015-0026-8.

17. Pearlman A.N., Chandra R.K., Chang D. et al. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am. J. Rhinol. Allergy. 2009; 23 (2): 145-148. DOI: 10.2500/ajra.2009.23.3284.

18. Schleich F.N., Manise M., Sele J. et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm. Med. 2013; 13: 11. DOI: 10.1186/1471-2466-13-11.

19. Nenasheva N.M. [The role of biomarkers in diagnosis and treatment of asthma]. Prakticheskaya pul'monologiya. 2017; (4): 3-9 (in Russian).

20. Yeganeh B., Xia C., Movassagh H. et al. Emerging mediators of airway smooth muscle dysfunction in asthma. Pulm. Pharmacol. Ther. 2013; 26 (1): 105-111. DOI: 10.1016/j.pupt.2012.06.011.

21. Raedler D., Ballenberger N., Klucker E. et al. Identification of novel immune phenotypes for allergic and nonallergic childhood asthma. J. Allergy Clin. Immunol. 2015; 135 (1): 81-91. DOI: 10.1016/j.jaci.2014.07.046.

22. Berraies A., Hamdi B., Ammar J. et al. Increased expression of thymic stromal lymphopoietin in induced sputum from asthmatic children. Immunol. Lett. 2016; 178: 85-91. DOI: 10.1016/j.imlet.2016.08.004.

23. Cheng J., Ouyang H., Du J. Expression and regulation of interleukin-37 in pathogenesis of nasal polyps. Indian J. Otolaryngol. Head Neck Surg. 2014; 66: 401-406. DOI: 10.1007/s12070-014-0725-3.

24. Galitskaya M.A., Shilovskiy I.P., Nikonova A.A. et al. Increased IL-33 expression in atopic bronchial asthma patients with confirmed viral respiratory infection. Allergy: Eur. J. Allergy Clin. Immunol. 2018; 73 (Suppl. 105): 298.